Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma

被引:30
作者
McCaughan, Georgia J. B. [3 ]
Fulham, Michael J. [1 ,3 ]
Mahar, Annabelle [3 ]
Soper, Judy [3 ,4 ]
Hong, Angela M. [1 ,2 ]
Stalley, Paul D. [3 ]
Tattersall, Martin H. N. [1 ,2 ]
Bhadri, Vivek A. [1 ,2 ]
机构
[1] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia
[2] Chris OBrien Lifehouse, 119-143 Missenden Rd, Camperdown, NSW 2050, Australia
[3] Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia
[4] Specialist Magnet Resonance Imaging, Newton, NSW, Australia
来源
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2016年 / 9卷
关键词
Ewing sarcoma; Immunotherapy; Anti-programmed cell death-1 antibody; Case report; GENOMIC INSTABILITY; CANCER; SURVIVAL; EXPERIENCE; NIVOLUMAB; ANTIBODY; THERAPY; REPAIR; FAMILY; TUMORS;
D O I
10.1186/s13045-016-0278-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Ewing sarcoma (EWS) is a malignant tumour of bone and soft tissue, and although many patients are cured with conventional multimodal therapy, those with recurrent or metastatic disease have a poor prognosis. Genomic instability and programmed cell death ligand-1 (PD-L1) expression have been identified in EWS, providing a rationale for treatment with agents that block the programmed cell death-1 (PD-1) receptor. Case presentation: In this report, we describe a heavily pre-treated patient with recurrent metastatic EWS who achieved a clinical and radiological remission with PD-1 blockade. Conclusions: To our knowledge, this is the first reported case demonstrating efficacy of PD-1 blockade in EWS. This warrants further investigation in particular given the poor prognosis in patients with recurrent or metastatic disease.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights
    Schalper, Kurt A.
    Venur, Vyshak Alva
    Velcheti, Vamsidhar
    JOURNAL OF RECEPTOR LIGAND AND CHANNEL RESEARCH, 2015, 8 : 1 - 7
  • [22] Programmed cell death-1 inhibition in lymphoma
    Hawkes, Eliza A.
    Grigg, Andrew
    Chong, Geoff
    LANCET ONCOLOGY, 2015, 16 (05) : E234 - E245
  • [23] Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
    Quispel-Janssen, Josine
    van der Noort, Vincent
    de Vries, Jeltje F.
    Zimmerman, Marion
    Lalezari, Ferry
    Thunnissen, Erik
    Monkhorst, Kim
    Schouten, Robert
    Schunselaar, Laurel
    Disselhorst, Maria
    Klomp, Houke
    Hartemink, Koen
    Burgers, Sjaak
    Buikhuisen, Wieneke
    Baas, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1569 - 1576
  • [24] Combined Effects of Programmed Cell Death-1 Blockade and Endostar on Brain Metastases of Lung Cancer
    Qi, Xuejiao
    Zhao, Yinlong
    Yang, Song
    Sun, YuMeng
    Liu, Honglei
    Liu, Pengyu
    Feng, Shiyao
    Tui, Hongbo
    Yuan, Zheng
    Yang, Jiankai
    Bu, Hui
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (06) : 709 - 716
  • [25] Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
    Onoyama, Takumi
    Takeda, Yohei
    Yamashita, Taro
    Hamamoto, Wataru
    Sakamoto, Yuri
    Koda, Hiroki
    Kawata, Soichiro
    Matsumoto, Kazuya
    Isomoto, Hajime
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (03) : 353 - 365
  • [26] Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance
    Liao, Xiyi
    Zhao, Liang
    Wu, Sangang
    Zheng, Hua
    Chen, Haojun
    Zhang, Huan
    Wang, ZiJing
    Lin, Qin
    ONCOTARGET, 2017, 8 (68) : 113287 - 113293
  • [27] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma
    Cheah, Chan Yoon
    Fowler, Nathan H.
    Neelapu, Sattva S.
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (05) : 384 - 391
  • [28] Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
    Kamata, Toshiko
    Suzuki, Akane
    Mise, Naoko
    Ihara, Fumie
    Takami, Mariko
    Makita, Yuji
    Horinaka, Atsushi
    Harada, Kazuaki
    Kunii, Naoki
    Yoshida, Shigetoshi
    Yoshino, Ichiro
    Nakayama, Toshinori
    Motohashi, Shinichiro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (12) : 1477 - 1489
  • [29] MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted?
    Zanella, Anais
    Doussot, Alexandre
    Puzenat, Eve
    Aubin, Francois
    Nardin, Charlee
    MELANOMA RESEARCH, 2020, 30 (06) : 606 - 607
  • [30] Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines in vitro and in vivo
    Zhang, Rui
    Lyu, Cuicui
    Lu, Wenyi
    Pu, Yedi
    Jiang, Yanyu
    Deng, Qi
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 2800 - 2812